Policy & Regulation
Hansa Biopharma reports divestiture of Equity Holding in Genovis
15 April 2019 -

Immunomodulatory enzyme technology company Hansa Biopharma AB (NASDAQ Stockholm: HNSA) revealed on Friday the completion of the sale its entire equity stake in Genovis AB (NASDAQ Stockholm:GENO) for gross proceeds of SEK89m.

Proceeds may be used by Hansa for working capital, to expedite the clinical development programme of imlifidase in transplant rejection and autoimmune diseases, to ramp up preparations for clinical studies with the recently selected lead in the NiceR-programme for development of novel IgG-cleaving enzymes for repeat dosing.

Genovis is reportedly engaged in the development of enzymatic research tools and technologies, applied in e.g. development and quality control of antibody-based drugs.

Earlier in 2011, Hansa Biopharma made a strategic and financial investment in Genovis.